Investors > News Releases
Sep 05, 2019
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment
Pipeline
Aug 30, 2019
Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference
Corporate
Aug 22, 2019
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention
Products
Aug 13, 2019
Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
Financial
Aug 07, 2019
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
Pipeline
Aug 06, 2019
Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019
Financial
Jun 27, 2019
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
Products
Jun 25, 2019
Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
Products
Jun 19, 2019
Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan
Products
Jun 05, 2019
Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference
Corporate
Jun 03, 2019
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
Products
Jun 02, 2019
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
Pipeline
May 14, 2019
Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
Products
May 09, 2019
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy
Pipeline
May 07, 2019
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
Financial